NasdaqGS:APLS

Stock Analysis Report

Executive Summary

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases.

Snowflake

Fundamentals

Adequate balance sheet and slightly overvalued.


Similar Companies

Share Price & News

How has Apellis Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

5.7%

APLS

1.7%

US Biotechs

1.3%

US Market


1 Year Return

64.1%

APLS

-8.8%

US Biotechs

5.9%

US Market

Return vs Industry: APLS exceeded the US Biotechs industry which returned -8.8% over the past year.

Return vs Market: APLS exceeded the US Market which returned 5.9% over the past year.


Shareholder returns

APLSIndustryMarket
7 Day5.7%1.7%1.3%
30 Day-5.3%-3.5%-1.9%
90 Day-4.2%-3.1%-1.8%
1 Year64.1%64.1%-8.0%-8.8%8.3%5.9%
3 Yearn/a13.9%9.9%45.6%36.2%
5 Yearn/a3.8%-1.2%66.1%47.9%

Price Volatility Vs. Market

How volatile is Apellis Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Apellis Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Undervalued: APLS ($25.56) is trading below our estimate of fair value ($101.84)

Significantly Undervalued: APLS is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: APLS is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: APLS is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate APLS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: APLS is overvalued based on its PB Ratio (10.2x) compared to the US Biotechs industry average (2.5x).


Next Steps

Future Growth

How is Apellis Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

27.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: APLS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: APLS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: APLS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if APLS's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if APLS's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: APLS is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Apellis Pharmaceuticals performed over the past 5 years?

-48.9%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: APLS is unprofitable, and losses have increased over the past 5 years at a rate of -48.9% per year.

Accelerating Growth: Unable to compare APLS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: APLS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (78.4%).


Return on Equity

High ROE: APLS has a negative Return on Equity (-122.01%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: APLS is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: APLS is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Apellis Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: APLS's short term assets ($308.4M) exceeds its short term liabilities ($35.6M)

Long Term Liabilities: APLS's short term assets (308.4M) exceeds its long term liabilities (122.0M)


Debt to Equity History and Analysis

Debt Level: APLS's debt to equity ratio (4.2%) is considered satisfactory

Reducing Debt: Insufficient data to determine if APLS's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: APLS has a low level of unsold assets or inventory.

Debt Coverage by Assets: APLS's debt is covered by short term assets (assets are 46.077080x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: APLS has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: APLS has less than a year of cash runway if free cash flow continues to reduce at historical rates of -68.2% each year


Next Steps

Dividend

What is Apellis Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage2.0%forecastin3Years0%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate APLS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate APLS's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if APLS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if APLS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of APLS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Apellis Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

2.0yrs

Average management tenure


CEO

Cedric Francois (47yo)

10.1yrs

Tenure

US$4,074,540

Compensation

Dr. Cedric Francois, M.D., Ph.D. serves as Principal of Vista Therapeutics, Inc. Dr. Francois co-founded Apellis Pharmaceuticals, Inc. in 2009 and has been its Chief Executive Officer and President since S ...


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether Cedric's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Cedric's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

2.0yrs

Average Tenure

46.5yo

Average Age

Experienced Management: APLS's management team is considered experienced (2 years average tenure).


Board Age and Tenure

6.3yrs

Average Tenure

47yo

Average Age

Experienced Board: APLS's board of directors are considered experienced (6.3 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$7,499,99213 Mar 19
The Morningside Group Limited
EntityCompany
Shares441,176
Max PriceUS$17.00

Ownership Breakdown


Management Team

  • Alec Machiels (46yo)

    Co-Founder & Director

    • Tenure: 10.1yrs
    • Compensation: US$61.00k
  • Federico Grossi (45yo)

    • Tenure: 0yrs
    • Compensation: US$2.76m
  • Cedric Francois (47yo)

    Co-Founder

    • Tenure: 10.1yrs
    • Compensation: US$4.07m
  • Pascal Deschatelets (49yo)

    Co-Founder & COO

    • Tenure: 10.1yrs
    • Compensation: US$1.86m
  • Tim Sullivan (48yo)

    Chief Financial Officer

    • Tenure: 2yrs
    • Compensation: US$859.75k
  • David Watson (46yo)

    General Counsel & VP of Corporate Development

    • Tenure: 5.8yrs
    • Compensation: US$251.25k
  • Lukas Scheibler (48yo)

    Chief Innovation Officer

    • Tenure: 1.5yrs
    • Compensation: US$3.74m
  • Lucia Celona (53yo)

    Chief People Officer

    • Tenure: 0.3yrs
  • Adam Townsend (42yo)

    Chief Commercial Officer

    • Tenure: 0.9yrs
  • Ahmad Sadr (45yo)

    Senior Vice President of Technical Operations

    • Tenure: 0.7yrs

Board Members

  • Alec Machiels (46yo)

    Co-Founder & Director

    • Tenure: 10.1yrs
    • Compensation: US$61.00k
  • Gerald Chan (68yo)

    Chairman of the Board

    • Tenure: 6.3yrs
    • Compensation: US$73.00k
  • Stephanie O’Brien (61yo)

    Director

    • Tenure: 6.3yrs
    • Compensation: US$62.00k
  • Cedric Francois (47yo)

    Co-Founder

    • Tenure: 10.1yrs
    • Compensation: US$4.07m
  • Gabriel Coscas

    Member of AMD Scientific Advisory Board

    • Tenure: 4.3yrs
  • Robert Brodsky

    Member of PNH Scientific Advisory Board

    • Tenure: 4.3yrs
  • Mike Yeadon

    Member of Pulmonology Scientific Advisory Board

    • Tenure: 4.3yrs
  • A. Dunlop (47yo)

    Director

    • Tenure: 9.6yrs
    • Compensation: US$52.00k
  • Marsha Wills-Karp

    Member of Pulmonology Scientific Advisory Board

    • Tenure: 0yrs
  • Carl Atkinson

    Member of Pulmonology Scientific Advisory Board

    • Tenure: 4.3yrs

Company Information

Apellis Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Apellis Pharmaceuticals, Inc.
  • Ticker: APLS
  • Exchange: NasdaqGS
  • Founded: 2009
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.631b
  • Shares outstanding: 63.81m
  • Website: https://www.apellis.com

Number of Employees


Location

  • Apellis Pharmaceuticals, Inc.
  • 6400 Westwind Way
  • Suite A
  • Crestwood
  • Kentucky
  • 40014
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
APLSNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDNov 2017
1JKDB (Deutsche Boerse AG)YesCommon StockDEEURNov 2017

Biography

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammator ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/14 03:18
End of Day Share Price2019/10/11 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.